EX-1.1
from 8-K
3 pages
Reference Is Made to the at the Market Offering Agreement, Dated as of February 27, 2023, as Amended on March 17, 2025 (The “Atm Agreement”), Between Protalix Biotherapeutics, Inc. (The “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”). This Letter (The “Amendment”) Constitutes an Agreement Between the Company and Wainwright to Amend the Atm Agreement as Set Forth Herein. Defined Terms That Are Used but Not Defined Herein Shall Have the Meanings Ascribed to Such Terms in the Atm Agreement. 1. the Defined Term “Agreement” in the Atm Agreement Is Amended to Mean the Atm Agreement as Amended by This Amendment. 2. the First Sentence in the Third Paragraph of the Atm Agreement Is Hereby Amended and Restated as Follows
12/34/56